Proof-of-Concept for Liquid Biopsy Disease Monitoring of MYC -Amplified Group 3 Medulloblastoma by Droplet Digital PCR.
Natalia StepienDaniel SenfterJulia FurtnerChristine HaberlerChristian DorferThomas CzechDaniela Lötsch-GojoLisa MayrCora HedrichAlicia BaumgartnerMaria Aliotti-LippolisHannah SchnedJohannes HollerKatharina BrucknerIrene SlavcAmedeo A AziziAndreas PeyrlLeonhard MüllauerSibylle MadlenerJohannes GojoPublished in: Cancers (2023)
amplification in the CSF of MB patients. These results warrant implementation of liquid biopsy in future prospective clinical trials to validate the potential for improved diagnosis, disease staging and monitoring.
Keyphrases
- quality improvement
- clinical trial
- end stage renal disease
- ejection fraction
- newly diagnosed
- ultrasound guided
- prognostic factors
- chronic kidney disease
- lymph node
- peritoneal dialysis
- fine needle aspiration
- transcription factor
- primary care
- randomized controlled trial
- high throughput
- pet ct
- healthcare
- patient reported outcomes
- risk assessment
- open label
- human health
- study protocol